H3N2 NA Subtype HA Specific Neutra™ Antibody Products

Are you grappling with the rapid antigenic drift of H3N2 influenza or the limitations of current NA inhibitors? Creative Biolabs' H3N2 NA Specific Neutra™ Antibody Products empower your research with high-precision, structure-guided neutralizing antibodies, enabling you to dissect viral escape mechanisms and develop next-generation, broad-spectrum therapeutics.

Introduction to Influenza A Virus H3N2 Neuraminidase (H3N2 NA)

Influenza A virus H3N2 Neuraminidase is a critical surface glycoprotein and a primary target for antiviral interventions. As a key driver of seasonal influenza epidemics, its functional integrity is essential for viral fitness and pathogenesis. H3N2 NA is a type II transmembrane protein with enzymatic activity. It cleaves sialic acid residues from host cell receptors, facilitating the release and spread of progeny virions from infected cells.

• Structural Insights

The NA head domain features a conserved enzymatic active site surrounded by highly variable antigenic loops. Recent cryo-EM structures reveal the dynamic nature of these loops and the presence of secondary, non-catalytic sialic acid binding sites, which influence antibody recognition and neutralization breadth.

Fig.1 NA is structured as a tetramer composed of four identical monomer units.¹

• Resistance and Signaling Pathways

Widespread use of NA inhibitors has led to the emergence of drug-resistant strains harboring mutations in the active site. NA activity also intersects with host signaling; by desialylating surface proteins, NA can modulate immune cell function and inflammatory responses, including the TLR and cytokine signaling pathways.

• Clinical Impact

H3N2 influenza causes significant annual morbidity and mortality, particularly in high-risk groups (elderly, young children, immunocompromised). It is a major contributor to seasonal epidemics, often associated with severe respiratory complications and increased hospitalizations.

• Antibodies Against H3N2 NA Subtype HA

Neutralizing antibodies targeting H3N2 NA offer a complementary strategy to hemagglutinin (HA)-focused immunity. They can inhibit enzymatic activity, block virion release, and mediate effector functions. Antibodies targeting conserved epitopes, including those adjacent to the active site or the secondary binding sites, are particularly valuable as they can exhibit broad reactivity against drifted strains and show potential in mitigating drug resistance.

Applications of Anti-H3N2 NA Neutralizing Antibodies

Fig.2 Phylogenetic analysis of N2 NA from H3N2 viruses and functional assessment of NA-specific antibodies.²

• Therapeutic Intervention for Severe Influenza

Anti-H3N2 NA neutralizing antibodies provide a direct antiviral mechanism, especially against NA inhibitor-resistant strains. In preclinical models, administration of broad-spectrum anti-NA monoclonal antibodies reduces viral lung titers and improves survival rates. Their mechanism—blocking viral egress—complements HA-targeting antibodies that prevent entry, offering a potent combination therapy for severe cases and hospitalized patients.

• Prophylaxis in High-Risk Populations

Prophylactic administration of anti-NA antibodies can confer immediate protection for immunocompromised individuals or those with suboptimal vaccine responses. This passive immunization strategy is crucial in outbreak settings, such as nursing homes, where H3N2 often causes severe outbreaks. It provides a rapid shield during the gap between vaccination and immune response development.

• Diagnostic and Surveillance Tool Development

High-specificity anti-NA antibodies are instrumental in developing rapid diagnostic tests to distinguish influenza subtypes and detect emerging variants. Furthermore, they are used in serological assays to quantify NA-specific antibody responses in vaccinated or convalescent individuals, providing critical data for assessing vaccine immunogenicity and population immunity against circulating H3N2 strains.

Our Anti-H3N2 NA Specific Neutra™ Antibody Products

Creative Biolabs delivers a premium portfolio of antibodies engineered for excellence in H3N2 research and development:

• High Neutralization Potency: Rigorously validated in functional neuraminidase inhibition assays and plaque reduction neutralization tests.
• Broad-Spectrum Recognition: Selected clones target conserved epitopes, offering activity against a panel of genetically diverse H3N2 clinical isolates.
• Precise Epitope Mapping: Antibodies are characterized for binding to defined structural domains, enabling mechanistic studies on viral escape and antibody synergy.
• Multi-Application Validated: Guaranteed performance in key techniques including ELISA, Western Blot, Immunofluorescence, and Neutralization Assays.

With more than twenty years of experience in antibody engineering, Creative Biolabs serves as your committed collaborator in virology research. We integrate profound scientific knowledge with advanced development platforms to supply researchers with trustworthy, high-performance reagents. Our H3N2 NA Specific Neutra™ Antibody Products are crafted to expedite your journey from discovery to therapeutic and diagnostic applications.

Reach out to our scientific team today to delve into our antibody portfolio, discuss custom development projects, or request comprehensive validation data. Together, let us address the challenges posed by H3N2 influenza.

References

1. McAuley, Julie L., et al. "Influenza virus neuraminidase structure and functions." Frontiers in microbiology 10 (2019): 39. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3389/fmicb.2019.00039
2. Stadlbauer, Daniel, et al. "Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site." Nature Communications 13.1 (2022): 7864. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s41467-022-35586-7